Loading…
← CockpitCompetitor Analysis › 601607.SS Shanghai Pharmaceuticals Holding Co. Ltd. Class AOpen in the cockpit ↗

Shanghai Pharmaceuticals Holding Co. Ltd. Class A601607.SSCompetitor analysis, valuation and peers

China · CNY·Health Care›Pharmaceuticals: Major

One of China's largest pharma distributors, also manufacturing generic and branded drugs.

≈ China's McKesson, with an in-house drugmaker attachedMomentum leader 90
Mkt cap
$8.23B
US dollars, full cap
Free float
23%
of shares outstanding
$/day
$34.9M
20-day average traded
Fwd P/E
11.2×
forward earnings
ROIC−WACC
+1.6 pp
WACC 5.0%
Hurdle
-18 pp
Req g minus delivered
Next earnings
134 days
1 Apr 2027
Close · CNYCN¥16.66
1D+0.7%
1W+2.8%
1M+1.3%
3M-0.7%
6M-0.4%
YTD-6.7%
1Y-6.5%
ATR %1.7%
52w lowhigh10.2% off high

What Shanghai Pharmaceuticals does

One of China's largest pharma distributors, also manufacturing generic and branded drugs.

Distribution brings most of the revenue but at thin margins, as it earns the mark-up between drug makers and hospitals; manufacturing is smaller but more profitable. Hospital sales depend on provincial tenders and national volume-based buying programmes that cut drug prices. Shanghai Pharmaceuticals Group, owned by the Shanghai city government, is the main shareholder.

In one line: China's McKesson, with an in-house drugmaker attached.

Products and services

  • Drug distribution / wholesale
  • Branded generics manufacturing
  • Retail pharmacy
  • TCM products

Customers

  • Hospitals
  • Pharmacies
  • Clinics

Where it sits in the supply chain

  • Health care
  • Pharma distribution & manufacturing
  • Wholesale + branded generics

What could go right

  • Consolidation of a fragmented distribution market
  • Specialty/oncology drug distribution growth

What could go wrong

  • Thin distribution margins
  • Government price controls

Moat: narrow (scale, distribution, regulatory licence). One of China's 'big four' pharma distributors with a nationwide logistics network.

Headquarters: Shanghai, China · Founded: 1998 · Employees: 49,608

Named competitors

Shanghai Pharmaceuticals at a glance

Size Shanghai Pharmaceuticals (601607.SS) is a China Health Care company (Pharmaceuticals: Major) with a market value of $8.23B, the 284th largest of 4,790 China companies the cockpit tracks. Shares closed at CN¥16.66 on 18 Nov 2026.

Performance Over six months the shares fell 0.4%, against +12.4% for the median peer and -20.0% for the China market (cap-weighted) — 9th lowest of 21 in its peer set.

Growth Revenue grew 3.8% over the last twelve months (peer median +15.3%); the operating margin is 3.0% (peer median 16.4%).

Valuation It trades at 11.2× forward earnings against a peer median of 32.4× (2nd cheapest of 14).

Price implies For today's price to make sense, revenue must grow about -10% a year for seven years (Req g). Recent delivered growth is +8%, so the hurdle is -18 pp: the price already allows for a slowdown.

Capital Return on invested capital runs 1.6 points above its cost of capital (5.0% WACC).

Next results Next results expected around 1 Apr 2027 (exchange calendar; dates can move).

Relative performance

10011021 May 202621 Aug 202618 Nov 2026Peer median 113601607.SS 101
Six months, rebased to 100: Shanghai Pharmaceuticals against the median of its 20 peers (local-currency closes).

Shanghai Pharmaceuticals financials

Reported figures in CNY; fiscal year ends 2025-12-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
RevenueCN¥291BCN¥283BCN¥275BCN¥260BCN¥231B
Revenue growth—+3%+6%+12%—
Gross profitCN¥32.3BCN¥28.0BCN¥28.4BCN¥29.0BCN¥28.4B
EBITDAn/aCN¥11.2BCN¥11.3BCN¥10.6BCN¥10.3B
Net incomeCN¥5.16BCN¥5.72BCN¥4.55BCN¥3.77BCN¥5.62B
Free cash flowCN¥7.39BCN¥4.36BCN¥4.77BCN¥3.24BCN¥2.94B
Capital expenditureCN¥2.26BCN¥2.33BCN¥2.40BCN¥2.97BCN¥2.68B
Total debtCN¥59.1BCN¥66.1BCN¥63.9BCN¥58.6BCN¥50.5B

Quarterly statements and history in the cockpit →

Shanghai Pharmaceuticals competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

-25%0%+25%+50%+75%-20%0%+20%RYTMPTGX4151GLENMARKPRAXALK-BALKS2196AMRXGRFKNSACORTHLUN-A4528MDGL002821CYTKIBRXBANBSYRE601607.SS6-month return →1-month return →
Up and to the right = strong over both horizons. Shanghai Pharmaceuticals is the large dot.

Fundamentals: revenue growth against valuation

0%+50%+100%+150%0×500×1,000×1,500×PTGX4151GLENMARKKNSACORTMDGL002821601607.SSRevenue growth (TTM) →Forward P/E →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. Shanghai Pharmaceuticals is the large dot.

Capital: growth delivered against growth the price implies

0%+20%+40%0%20%40%PTGX4151GLENMARKALK-BALKS2196AMRXGRFKNSACORTHLUN-A601607.SSGrowth delivered (Del g) →Growth the price implies (Req g, 7 yrs) →
Above the diagonal = the price needs more growth than the company has been delivering; below = the price already allows for a slowdown. Shanghai Pharmaceuticals is the large dot.

Shanghai Pharmaceuticals competitors and peer comparison

Head to head with its named competitors (601607.SS vs 1099.HK vs 3320.HK vs 600998.SS)
CompanyMarket cap6M returnRevenue growthOp. marginForward P/EReq g
Shanghai Pharmaceuticals 601607.SS$8.23B0%+4%3%11.2×-10.1%
Sinopharm 1099.HK$6.74B0%+3%3%6.2×-7.3%
China Resources Pharmaceutical 3320.HK$3.60B-7%+8%4%5.8×-4.9%
Jointown Pharmaceutical 600998.SS$3.99B+7%+9%2%11.8×0.2%
Shanghai Fosun Pharmaceutical (Group) 600196.SS$7.57B-14%+8%6%14.8×2.9%

How Shanghai Pharmaceuticals compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

Shanghai Pharmaceuticals against its 20 peers (data as of 18 Nov 2026)
Measure601607.SSPeer medianRank in peer set
1-month return+1.3%+4.2%9th lowest of 21
6-month return-0.4%+12.4%9th lowest of 21
Distance from 52-week high-10.2%-10.8%10th highest of 21
Revenue growth (TTM)+3.8%+15.3%5th lowest of 20
Operating margin3.0%16.4%5th lowest of 19
Forward P/E11.2×32.4×2nd cheapest of 14
Growth the price implies (Req g, 7 yrs)-10.1%13.8%least demanding of 13
Growth delivered (Del g)+8.1%+9.3%5th lowest of 13
Hurdle (Req g minus delivered)-18.2 pp+3.7 pp2nd least demanding of 13
ROIC minus cost of capital+1.6 pp+3.1 pp8th lowest of 17

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginForward P/EReq gDelivered g
Shanghai Pharmaceuticals 601607.SSChina$8.23B0%+4%3%11.2×-10.1%+8.1%
Rhythm Pharmaceuticals RYTMUnited States$8.25B+31%+61%-67%n/an/an/a
Protagonist Therapeutics PTGXUnited States$8.30B+26%+164%59%1,532.5×17.5%+10.0%
Kyowa Kirin 4151.TJapan$8.43B+9%+10%24%16.4×-4.7%+9.3%
Glenmark Pharmaceuticals GLENMARK.NSIndia$7.98B+10%0%17%33.1×27.3%+9.4%
Praxis Precision Medicines PRAXUnited States$8.53B-9%-100%n/an/an/an/a
ALK-abello A/S ALK-B.CODenmark$7.94B-8%+16%26%34.8×7.3%+12.6%
Alkermes Public ALKSUnited States$7.87B+27%+15%5%n/a32.5%+7.3%
Shanghai Fosun Pharmaceutical (Group) 2196.HKHong Kong$7.74B-15%+10%6%9.0×19.9%+5.8%
Amneal Pharmaceuticals AMRXUnited States$7.62B+79%+9%16%19.2×17.2%+8.7%
Grifols GRF.MCSpain$7.48B+19%+1%16%13.1×7.1%+7.1%
Kiniksa Pharmaceuticals International KNSAUnited States$7.47B+75%+58%14%56.6×10.4%+45.5%
Corcept Therapeutics CORTUnited States$7.42B+15%+30%12%15.3×23.9%+16.6%
H. Lundbeck A/S HLUN-A.CODenmark$9.16B+69%+9%26%n/a-6.6%+6.6%
ONO Pharmaceutical 4528.TJapan$7.33B-2%-2%22%15.3×-6.8%+10.8%
Madrigal Pharmaceuticals MDGLUnited States$9.25B-22%+93%-11%81.5×n/an/a
Asymchem Laboratories (Tianjin) 002821.SZChina$7.27B+20%+18%17%37.4×n/an/a
Cytokinetics CYTKUnited States$7.15B-35%+30%-625%n/an/an/a
ImmunityBio IBRXUnited States$7.13B-17%+121%-150%n/an/an/a
Bachem BANB.SWSwitzerland$7.06B0%+5%19%32.4×n/an/a
Spyre Therapeutics SYREUnited States$9.64B+41%n/an/an/an/an/a

Questions

Who are Shanghai Pharmaceuticals's main competitors?
Named competitors: Sinopharm (1099.HK), China Resources Pharma (3320.HK), Jointown Pharmaceutical (600998.SS), Fosun Pharma (600196.SS). The cockpit's measured peer set (industry) also includes Rhythm Pharmaceuticals (RYTM), Protagonist Therapeutics (PTGX), Kyowa Kirin (4151.T), Glenmark Pharmaceuticals (GLENMARK.NS), Praxis Precision Medicines (PRAX), ALK-abello A/S (ALK-B.CO).
Is Shanghai Pharmaceuticals expensive compared with its peers?
On forward p/e it trades at 11.2× against a peer median of 32.4×, 2nd cheapest of 14 in its peer set. For today's price to make sense, revenue must grow about -10% a year for seven years (Req g). Recent delivered growth is +8%, so the hurdle is -18 pp: the price already allows for a slowdown.
How has Shanghai Pharmaceuticals stock performed?
Over six months to 18 Nov 2026 the shares returned -0.4% against +12.4% for the median peer; over one year -6.5%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.